Evotec SE ADR - Asset Resilience Ratio
Evotec SE ADR (EVO) has an Asset Resilience Ratio of 3.47% as of March 2026. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See how liquid is Evotec SE ADR's working capital to evaluate short-term liquidity relative to the company's equity base.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2003–2025)
This chart shows how Evotec SE ADR's Asset Resilience Ratio has changed over time. For the complete balance sheet picture, see Evotec SE ADR asset portfolio.
Liquid Assets Composition Over Time
This chart breaks down Evotec SE ADR's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. Explore EVO long-term investments to assets to see how much of total assets are deployed in long-term investments.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 0% |
| Short-term Investments | $56.91 Million | 3.47% |
| Total Liquid Assets | $56.91 Million | 3.47% |
Asset Resilience Insights
- Limited Liquidity: Evotec SE ADR maintains only 3.47% of assets in liquid form.
- This low level may indicate efficient asset utilization but could pose risks during economic downturns.
- The company has significant short-term investments, indicating active treasury management.
Evotec SE ADR Industry Peers by Asset Resilience Ratio
Compare Evotec SE ADR's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Kamada
TA:KMDA |
Drug Manufacturers - Specialty & Generic | 0.00% |
|
Takeda Pharmaceutical Co Ltd ADR
NYSE:TAK |
Drug Manufacturers - Specialty & Generic | 4.94% |
|
Viatris Inc
NASDAQ:VTRS |
Drug Manufacturers - Specialty & Generic | 1.48% |
|
Takeda Pharmaceutical Company Limited
F:TKDA |
Drug Manufacturers - Specialty & Generic | 0.69% |
|
Shijiazhuang Yiling Pharmaceutical Co Ltd
SHE:002603 |
Drug Manufacturers - Specialty & Generic | 11.60% |
|
Chengdu Kanghong Pharmaceuticals Group Co Ltd
SHE:002773 |
Drug Manufacturers - Specialty & Generic | 4.31% |
|
Yipinhong Pharmaceutical Co Ltd Class A
SHE:300723 |
Drug Manufacturers - Specialty & Generic | 1.01% |
|
Avadel Pharmaceuticals PLC
NASDAQ:AVDL |
Drug Manufacturers - Specialty & Generic | 5.90% |
Annual Asset Resilience Ratio for Evotec SE ADR (2003–2025)
The table below shows the annual Asset Resilience Ratio data for Evotec SE ADR.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2025-12-31 | 3.25% | $57.85 Million | $1.78 Billion | -1.47pp |
| 2024-12-31 | 4.73% | $90.41 Million | $1.91 Billion | +0.67pp |
| 2023-12-31 | 4.05% | $93.20 Million | $2.30 Billion | -9.53pp |
| 2022-12-31 | 13.58% | $306.61 Million | $2.26 Billion | +6.46pp |
| 2021-12-31 | 7.12% | $159.17 Million | $2.24 Billion | +3.17pp |
| 2020-12-31 | 3.95% | $72.62 Million | $1.84 Billion | +0.45pp |
| 2019-12-31 | 3.50% | $48.25 Million | $1.38 Billion | -1.79pp |
| 2018-12-31 | 5.29% | $40.82 Million | $771.88 Million | +0.11pp |
| 2017-12-31 | 5.18% | $34.56 Million | $667.27 Million | -7.32pp |
| 2016-12-31 | 12.50% | $43.92 Million | $351.37 Million | -18.85pp |
| 2015-12-31 | 31.35% | $90.46 Million | $288.54 Million | +13.01pp |
| 2014-12-31 | 18.35% | $41.21 Million | $224.60 Million | -4.74pp |
| 2013-12-31 | 23.09% | $52.49 Million | $227.38 Million | +11.30pp |
| 2012-12-31 | 11.79% | $26.57 Million | $225.43 Million | -9.30pp |
| 2011-12-31 | 21.08% | $46.01 Million | $218.21 Million | -3.65pp |
| 2010-12-31 | 24.73% | $47.45 Million | $191.86 Million | +7.38pp |
| 2009-12-31 | 17.35% | $25.43 Million | $146.60 Million | +1.47pp |
| 2008-12-31 | 15.87% | $29.03 Million | $182.90 Million | -12.09pp |
| 2007-12-31 | 27.97% | $58.14 Million | $207.88 Million | +17.98pp |
| 2006-12-31 | 9.99% | $20.53 Million | $205.53 Million | -40.25pp |
| 2005-12-31 | 50.24% | $93.50 Million | $186.11 Million | -34.42pp |
| 2004-12-31 | 84.66% | $60.03 Million | $70.91 Million | +9.14pp |
| 2003-12-31 | 75.52% | $31.51 Million | $41.73 Million | -- |
About Evotec SE ADR
Evotec SE operates as a drug discovery and development company in the United States, Germany, France, the United Kingdom, Switzerland, and internationally. It operates in two segments, Shared R&D and Just " Evotec Biologics. The company is developing pharmaceutical products in various therapeutic areas, such as oncology, autoimmune, cancer, diabetes, heart failure, immunology, pain and inflammati… Read more